FDA Antiperspirant Monograph Partial Stay Permits Enhanced Duration
This article was originally published in The Rose Sheet
Executive Summary
Under a partial stay of the OTC Antiperspirant Monograph, products claiming enhanced duration up to 48 hours will be permitted on the market while FDA reviews new data, the agency says in an Oct. 15 Federal Register notice
You may also be interested in...
Certain Dri Antiperspirant Study Supports 48-Hour Claims – Numark
Clinical testing by Numark Laboratories supports an "extra effective" enhanced duration claim for Certain Dri antiperspirant, according to the company
Certain Dri Antiperspirant Study Supports 48-Hour Claims – Numark
Clinical testing by Numark Laboratories supports an "extra effective" enhanced duration claim for Certain Dri antiperspirant, according to the company
OTC Antiperspirant Duration Claim Restrictions Contested By CTFA
Restricting enhanced duration claims under the OTC Antiperspirant Drug Products Final Monograph violates First Amendment principles and is inconsistent with FDA regulatory precedent, according to the Cosmetic, Toiletry and Fragrance Association